Prevention & Lipids
Blood pressure targets and treatment strategies
Also called HTN, high blood pressure, BP management
Sources: updated Oct 2, 2026
Synthesized from 9 evidence-backed clinical questions on Hypertension management — 4 supports benefit, 5 no benefit shown.
The placed evidence leans toward no benefit
4
Favor benefit
44% of all
5
No benefit shown
56% of all
Low certainty on 100% of questions
Does angiotensin-converting enzyme inhibitors vs angiotensin ii receptor blockers improve Stroke Hospitalization in Hypertensive disease?
Low Certainty− No benefit shownangiotensin-converting enzyme inhibitors vs Angiotensin ii receptor blockers · Stroke Hospitalization
2 studies (180,342 patients) provide low-certainty evidence against benefit of angiotensin-converting enzyme inhibitors for Stroke Hospitalization in Hypertensive disease.
Does antihypertensives vs placebo improve Stroke Hospitalization in Hypertension, Early-Onset, Autosomal Dominant, with Severe Exacerbation in Pregnancy?
Low Certainty+ Favors benefitantihypertensives vs placebo · Stroke Hospitalization
4 studies (107,912 patients) provide low-certainty evidence for benefit of antihypertensives for Stroke Hospitalization in Hypertension, Early-Onset, Autosomal Dominant, with Severe Exacerbation in Pregnancy.
Does antihypertensive therapy vs placebo improve All-Cause Mortality in Hypertensive disease?
Low Certainty− No benefit shownantihypertensive therapy vs placebo · All-Cause Mortality
2 studies (16,732 patients) provide low-certainty evidence against benefit of antihypertensive therapy for All-Cause Mortality in Hypertensive disease.
Does losartan vs placebo improve outcomes in Hypertensive disease?
Low Certainty− No benefit shownlosartan vs placebo · Left Ventricular Ejection Fraction
11 studies (9,193 patients) provide low-certainty evidence against benefit of losartan for Left Ventricular Ejection Fraction in Hypertensive disease.
Does captopril vs atenolol improve outcomes in Diabetes Mellitus, Type 2?
Low Certainty+ Favors benefitcaptopril vs Atenolol · Stroke Hospitalization
8 studies (7,624 patients) provide low-certainty evidence for benefit of captopril for Stroke Hospitalization in Diabetes Mellitus, Type 2.
Does dexmedetomidine vs placebo improve Acute Kidney Injury in Hypertensive disease?
Low Certainty+ Favors benefitdexmedetomidine vs placebo · Acute Kidney Injury
5 studies (5,769 patients) provide low-certainty evidence for benefit of dexmedetomidine for Acute Kidney Injury in Hypertensive disease.
The evidence sections above show what the literature supports; this is what the field is still arguing about. Open a debate for the camps, the named voices, and the vote.
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
University of Washington
h-index 214 · 191k citations
Most-cited researchers publishing on Hypertension management.
